Plain-English translation of NCT07359014 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new immunotherapy called CD19/BCMA dual-targeted CAR-T cell therapy for patients with multiple myeloma that has relapsed or become resistant to other treatments. The medication works by taking your own immune cells, training them in the lab to recognize and attack cancer cells, and then putting them back into your body. Early research suggests this dual-targeting approach may help patients who have already tried other therapies.
About half of patients who receive standard CAR-T therapy for multiple myeloma eventually relapse, leaving few good treatment options. This trial is testing whether targeting two cancer markers instead of one might be more effective and offer hope to patients whose cancer has come back or stopped responding to treatment.
You likely qualify if…
You likely don't qualify if…
If you qualify, doctors will first collect some of your blood cells through a process called apheresis (similar to donating plasma). Your cells will be sent to a lab where scientists will modify them with the new therapy and grow more of them. Once ready, the modified cells will be infused back into your body through an IV, likely during a hospital stay. You would then be monitored closely for side effects and response to treatment, with regular clinic visits and blood tests to track how well the medication is working.
AI-generated summary from trial data · Jun 28, 2026 · Not medical advice
China
Sponsor
Second Affiliated Hospital, School of Medicine, Zhejiang University
Collaborators
Tongji Hospital, Taizhou Hospital of Zhejiang Province affiliated to Wenzhou Medical University
Enrollment target
~25 participants
Started
November 2025
Primary completion
October 2027
Age range
18 Years – 75 Years
Last updated on clinicaltrials.gov in January 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xuzhao Zhang
Second Affiliated Hospital, School of Medicine, Zhejiang University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.